PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60M


The company is being sued by the development partner for its lead new drug candidate.

Previous Asset protection strategies for Ohio business owners
Next Elysian Tattoo Gallery filling former Floppy's space in Midtown